Mirum and Incyte Win FDA Approval for Atebrioz (Zilurgisertib) in Rare Bone Disease FOP

SentiSense · Published Sep 25, 2026, 4:11 PM ET · Updated Sep 26, 2026, 12:18 PM ET

The FDA approved Atebrioz (zilurgisertib) on September 25, 2026 to reduce new heterotopic ossification in adults and children 12 and older with fibrod...